Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Thrombolytic_Science_International> ?p ?o. }
Showing items 1 to 29 of
29
with 100 items per page.
- Thrombolytic_Science_International abstract "Thrombolytic Science International (TSI) is a private biopharmaceutical company beginning Phase I clinical trials of TS01, a new-generation therapy to treat acute strokes and heart attacks.Tissue plasminogen activator (tPA) has remained the only clot-dissolving, thrombolytic drug available for clinical use in patients with ischemic stroke since its approval in 1996. Only about 5% of stroke patients are treated with tPA because of its short treatment time-window, suboptimal efficacy, and risk of intra-cranial hemorrhage. TS01 is a clot-dissolving treatment consisting of a mutated form of the first-generation thrombolytic, pro-urokinase (pro-UK) preceded by a bolus of plasma complement 1 esterase inhibitor (C1-inhibitor).TS01 targets only the occlusive (bad) clots that lead to stroke, a fact which the company expects will significantly reduce the risk of bleeding. Like its parent molecule pro-UK, TS01 is also expected to show a longer treatment time-window than tPA. These attributes will allow many more patients to be treated with this potentially life-saving treatment.".
- Thrombolytic_Science_International industry Biotechnology.
- Thrombolytic_Science_International location Cambridge,_Massachusetts.
- Thrombolytic_Science_International type Privately_held_company.
- Thrombolytic_Science_International wikiPageExternalLink 757.full.
- Thrombolytic_Science_International wikiPageExternalLink tsillc.net.
- Thrombolytic_Science_International wikiPageExternalLink tsillc.net.
- Thrombolytic_Science_International wikiPageID "35892678".
- Thrombolytic_Science_International wikiPageRevisionID "593187423".
- Thrombolytic_Science_International hasPhotoCollection Thrombolytic_Science_International.
- Thrombolytic_Science_International subject Category:Biotechnology_companies_of_the_United_States.
- Thrombolytic_Science_International subject Category:Companies_based_in_Cambridge,_Massachusetts.
- Thrombolytic_Science_International subject Category:Privately_held_companies_based_in_Massachusetts.
- Thrombolytic_Science_International type Agent.
- Thrombolytic_Science_International type Company.
- Thrombolytic_Science_International type Organisation.
- Thrombolytic_Science_International type Organization.
- Thrombolytic_Science_International type Agent.
- Thrombolytic_Science_International type SocialPerson.
- Thrombolytic_Science_International type Thing.
- Thrombolytic_Science_International comment "Thrombolytic Science International (TSI) is a private biopharmaceutical company beginning Phase I clinical trials of TS01, a new-generation therapy to treat acute strokes and heart attacks.Tissue plasminogen activator (tPA) has remained the only clot-dissolving, thrombolytic drug available for clinical use in patients with ischemic stroke since its approval in 1996.".
- Thrombolytic_Science_International label "Thrombolytic Science International".
- Thrombolytic_Science_International sameAs m.0jwrcrh.
- Thrombolytic_Science_International sameAs Q7798341.
- Thrombolytic_Science_International sameAs Q7798341.
- Thrombolytic_Science_International wasDerivedFrom Thrombolytic_Science_International?oldid=593187423.
- Thrombolytic_Science_International homepage tsillc.net.
- Thrombolytic_Science_International isPrimaryTopicOf Thrombolytic_Science_International.
- Thrombolytic_Science_International name "Thrombolytic Science International, LLC (TSI)".